Frankfurt - Delayed Quote EUR

Oryzon Genomics S.A. (ORN.F)

Compare
1.5180 -0.0380 (-2.44%)
At close: December 20 at 8:15:49 AM GMT+1
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for ORN.F

Recent News: ORN.F

View More
ORYZON Continues to Strengthen its Patent Portfolio for Vafidemstat

ORYZON Continues to Strengthen its Patent Portfolio for Vafidemstat
GlobeNewswire 20 days ago
ORYZON Reports Financial Results and Corporate Update for Quarter Ended September 30, 2024

ORYZON Reports Financial Results and Corporate Update for Quarter Ended September 30, 2024
GlobeNewswire last month
ORYZON receives minutes from End-of-Phase II meeting with the FDA on the PORTICO-2 Phase III vafidemstat trial in Borderline Personality Disorder

ORYZON receives minutes from End-of-Phase II meeting with the FDA on the PORTICO-2 Phase III vafidemstat trial in Borderline Personality Disorder
GlobeNewswire 2 months ago
ORYZON Presents the Final Data From PORTICO, a Global Phase IIb Vafidemstat Trial in Borderline Personality Disorder (BPD), at the European College of Neuropsychopharmacology (ECNP) Congress

ORYZON Presents the Final Data From PORTICO, a Global Phase IIb Vafidemstat Trial in Borderline Personality Disorder (BPD), at the European College of Neuropsychopharmacology (ECNP) Congress
GlobeNewswire 2 months ago
ORYZON Receives “Intention to Grant” Communication for Patent Relating to the Use of Vafidemstat in Borderline Personality Disorder

ORYZON Receives “Intention to Grant” Communication for Patent Relating to the Use of Vafidemstat in Borderline Personality Disorder
GlobeNewswire 3 months ago
ORYZON Announces First Patient Dosed in an Investigator-Initiated Phase Ib Study of Iadademstat in First-Line Acute Myeloid Leukemia

ORYZON Announces First Patient Dosed in an Investigator-Initiated Phase Ib Study of Iadademstat in First-Line Acute Myeloid Leukemia
GlobeNewswire 3 months ago
ORYZON Continues to Strengthen its Patent Portfolio for Vafidemstat with Additional “Decision to Grant” Communications

ORYZON Continues to Strengthen its Patent Portfolio for Vafidemstat with Additional “Decision to Grant” Communications
GlobeNewswire 3 months ago
ORYZON to Provide Corporate Progress Updates at Several Events in September

ORYZON to Provide Corporate Progress Updates at Several Events in September
GlobeNewswire 3 months ago
ORYZON reports financial results and corporate update for half-year ending June 30, 2024

ORYZON reports financial results and corporate update for half-year ending June 30, 2024
GlobeNewswire 4 months ago
ORYZON Receives “Decision to grant” for Two Important Patents for Vafidemstat in Japan

ORYZON Receives “Decision to grant” for Two Important Patents for Vafidemstat in Japan
GlobeNewswire 5 months ago
ORYZON Announces Voting Results from its 2024 Annual General Meeting of Shareholders

ORYZON Announces Voting Results from its 2024 Annual General Meeting of Shareholders
GlobeNewswire 5 months ago
View More

Related Tickers

BXPHF Botanix Pharmaceuticals Limited
0.2580
0.00%
 
THRD Third Harmonic Bio, Inc.
10.84
-0.37%
 
BOT.AX Botanix Pharmaceuticals Limited
0.3600
-1.37%
 
FUM.L Futura Medical plc
31.95
-2.44%
 
ACXP Acurx Pharmaceuticals, Inc.
0.8250
+8.77%
 
MEIP MEI Pharma, Inc.
2.5000
+1.63%
 
CLGN CollPlant Biotechnologies Ltd.
3.4100
-6.83%
 
LXEO Lexeo Therapeutics, Inc.
6.28
+3.97%
 
OKUR OnKure Therapeutics, Inc.
8.38
+4.10%
 
CSBR Champions Oncology, Inc.
7.51
-0.60%